LKQ is trading lower today after its April 30, 2026 first-quarter report highlighted weaker profitability and a headline impairment charge. GAAP net income and EPS fell materially year over year, and the company recorded a $44 million other-than-temporary impairment related to its equity-method stake in Mekonomen, which weighed on reported results and market sentiment. (sec.gov)

For Q1 2026, LKQ reported revenue of about $3.47 billion, while net income was about $79 million and diluted EPS was about $0.31 (with GAAP EPS also commonly cited around $0.30 in recaps). The quarter included the $44 million Mekonomen impairment, and commentary around margin pressure has kept the focus on earnings power rather than the revenue growth. (tradingview.com)

The company lowered its full-year 2026 GAAP EPS outlook to $2.16–$2.46 (down from its prior range), which is being interpreted as a reset to reported earnings expectations following the quarter’s charges. At the same time, LKQ reaffirmed adjusted diluted EPS guidance of $2.90–$3.20 and reiterated its cash flow outlook, creating a split reaction between investors focused on GAAP optics versus those focused on adjusted earnings and cash generation. (sahmcapital.com)

LKQ said it concluded events in Q1 2026 signaled an other-than-temporary decline in the fair value of its Mekonomen investment, citing changes in financial condition including higher leverage and a discontinued dividend alongside a prolonged share-price decline and operational underperformance. Going forward, traders will watch for updates on LKQ’s strategic review process, any additional restructuring/impairment items, and whether buybacks accelerate given remaining authorization and management’s comments about repurchases later in 2026. (sec.gov)